Revenue
316 thousand USD
2026 Q2 · USD
Exact inputs and evidence
- Revenue: 315669 USD Source
Annual consolidated revenue for 2025: about USD 2.906M, using the latest reported figures. The previous period, 2024, was about USD 3.53M.
316 thousand USD
2026 Q2 · USD
-960.79%
2026 Q2 · %
-2.42 million USD
2026 Q2 · USD
1499603 USD
35118692 shares
77.31% · 15.3 million shares
Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.
The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.
1.81 million USD
2025-07-01 – 2026-06-30
-2.41 million USD
2024-01-01 – 2024-12-31
-7.2 million USD
2025-07-01 – 2026-06-30
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2026-10-28.
Financial data available through: 2025-12-31.
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Prior period
USD 3.53 million
–
Current period
USD 2.91 million
–
2905805 − 3530303 = -624498 USD
3530303 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source2905805 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceThe citation records this snapshot. The page link may show a newer release later.
Prior period
−USD 1.85 million
–
Current period
−USD 4.33 million
–
-4328034 − -1849474 = -2478560 USD
-1849474 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-4328034 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceThe citation records this snapshot. The page link may show a newer release later.
Comparable inputs unavailable for: Net income, Capital expenditure.
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
| Period | Revenue | Operating costs | Operating income | Tax, interest and other | Net income | Free cash flow | Source |
|---|---|---|---|---|---|---|---|
| 2024 2024-01-01 – 2024-12-31 | 3530303 | 15220303 Derived | -11690000 | -9279121 Derived | -2410879 | Unavailable | Source
|
| 2025 2025-01-01 – 2025-12-31 | 2905805 | 21245805 Derived | -18340000 | Unavailable | Unavailable | Unavailable | Source
|
Amounts are exact, in USD.
Sales over time and how quickly they are changing.
Revenue reported for each complete financial period.
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2024 | Revenue | 3530303 |
|
| 2025 | Revenue | 2905805 |
|
Change in revenue from the same financial period one year earlier.
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2024 | Year over year | No prior comparable period |
|
| 2025 | Year over year | -17.7% |
|
How much revenue becomes profit, and how much cash operations generate.
Operating income, net income and free cash flow as a share of revenue.
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2024 | Operating margin | -331.1% |
|
| 2025 | Operating margin | -631.2% |
|
| 2024 | Net margin | -68.3% |
|
| 2025-12-31 | Net margin | Not reported |
|
| 2024 | Free cash flow margin | Not reported |
|
| 2025 | Free cash flow margin | Not reported |
|
Cash generated by the company’s normal business operations.
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2024 | Operating cash flow | -1849474 |
|
| 2025 | Operating cash flow | -4328034 |
|
Operating cash flow minus capital expenditure for the same period and unit.
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2024 | Free cash flow | Unavailable |
|
| 2025 | Free cash flow | Unavailable |
|
Liabilities and short-term ability to meet obligations at each period end.
Total liabilities as a share of total assets.
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2024 | Liabilities / assets | 18.3% |
|
| 2025 | Liabilities / assets | 25.8% |
|
Current assets divided by current liabilities.
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2024 | Current assets / current liabilities | 0.67× |
|
| 2025 | Current assets / current liabilities | 0.16× |
|
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2021 2021-01-01 – 2021-12-31 | −USD 3,308 Exact valueExact value: -3308 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 461 Exact valueExact value: -461 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2022 2022-01-01 – 2022-12-31 | −USD 35,388 Exact valueExact value: -35388 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 4,235 Exact valueExact value: -4235 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2023 2023-01-01 – 2023-12-31 | USD 403,780 Exact valueExact value: 403780 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 818,766 Exact valueExact value: -818766 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2024 2024-01-01 – 2024-12-31 | −USD 2.41 million Exact valueExact value: -2410879 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 1.85 million Exact valueExact value: -1849474 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2025 2025-01-01 – 2025-12-31 | Unavailable Not reported for this period. | −USD 4.33 million Exact valueExact value: -4328034 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
24 filings · 911 latest values · 911 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0001840425, 1840425, edgar:1840425
Also known as BELLEVUE LIFE SCIENCES ACQUISITION CORP., Bellevue Life Sciences Acquisition Corp., OSR HOLDINGS, INC., OSR HEALTH, INC., OSR HOLDINGS, INC., OSR Health, Inc., OSR Holdings, Inc.